SA522431627B1 - متقارن واستخداماته - Google Patents
متقارن واستخداماتهInfo
- Publication number
- SA522431627B1 SA522431627B1 SA522431627A SA522431627A SA522431627B1 SA 522431627 B1 SA522431627 B1 SA 522431627B1 SA 522431627 A SA522431627 A SA 522431627A SA 522431627 A SA522431627 A SA 522431627A SA 522431627 B1 SA522431627 B1 SA 522431627B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- treatment
- conjugate
- present
- therapeutic molecule
- peptide carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911403.2A GB201911403D0 (en) | 2019-08-09 | 2019-08-09 | Conjugate and uses thereof |
| PCT/GB2020/051891 WO2021028666A1 (en) | 2019-08-09 | 2020-08-07 | Conjugate and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA522431627B1 true SA522431627B1 (ar) | 2024-05-19 |
Family
ID=67990936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522431627A SA522431627B1 (ar) | 2019-08-09 | 2022-02-08 | متقارن واستخداماته |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220275372A1 (https=) |
| EP (1) | EP4010030A1 (https=) |
| JP (1) | JP7678654B2 (https=) |
| KR (1) | KR20220079524A (https=) |
| CN (2) | CN114615998B (https=) |
| AU (1) | AU2020327659A1 (https=) |
| BR (1) | BR112022002309A2 (https=) |
| CA (1) | CA3149700A1 (https=) |
| GB (1) | GB201911403D0 (https=) |
| IL (1) | IL290424A (https=) |
| MX (1) | MX2022001712A (https=) |
| SA (1) | SA522431627B1 (https=) |
| WO (1) | WO2021028666A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US12465646B2 (en) | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| WO2022171972A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| EP4304657A4 (en) * | 2021-03-12 | 2026-04-01 | Pepgen Inc | METHODS OF TREATMENT OF TYPE 1 MYOTONIC DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES |
| KR20250116673A (ko) * | 2022-11-21 | 2025-08-01 | 펩젠 인크. | 세포-침투 펩티드, 그의 접합체 및 그의 사용 방법 |
| WO2025033255A1 (ja) * | 2023-08-07 | 2025-02-13 | 東亞合成株式会社 | ペプチドフラグメント及びその利用 |
| WO2025033256A1 (ja) * | 2023-08-07 | 2025-02-13 | 東亞合成株式会社 | ペプチドフラグメント及びその利用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2049664T1 (sl) * | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
| WO2009005793A2 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009147368A1 (en) * | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CN103998458B (zh) * | 2011-08-30 | 2018-10-09 | 医学研究理事会 | 具有中央疏水域的细胞穿透肽 |
| EP2900821B1 (en) * | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
-
2019
- 2019-08-09 GB GBGB1911403.2A patent/GB201911403D0/en not_active Ceased
-
2020
- 2020-08-07 AU AU2020327659A patent/AU2020327659A1/en active Pending
- 2020-08-07 JP JP2022507761A patent/JP7678654B2/ja active Active
- 2020-08-07 CN CN202080071067.8A patent/CN114615998B/zh active Active
- 2020-08-07 CA CA3149700A patent/CA3149700A1/en active Pending
- 2020-08-07 MX MX2022001712A patent/MX2022001712A/es unknown
- 2020-08-07 KR KR1020227007655A patent/KR20220079524A/ko active Pending
- 2020-08-07 EP EP20754817.3A patent/EP4010030A1/en active Pending
- 2020-08-07 CN CN202510582562.XA patent/CN120837670A/zh active Pending
- 2020-08-07 WO PCT/GB2020/051891 patent/WO2021028666A1/en not_active Ceased
- 2020-08-07 BR BR112022002309A patent/BR112022002309A2/pt unknown
- 2020-08-07 US US17/631,654 patent/US20220275372A1/en active Pending
-
2022
- 2022-02-07 IL IL290424A patent/IL290424A/en unknown
- 2022-02-08 SA SA522431627A patent/SA522431627B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114615998A (zh) | 2022-06-10 |
| US20220275372A1 (en) | 2022-09-01 |
| JP2022543320A (ja) | 2022-10-11 |
| JP7678654B2 (ja) | 2025-05-16 |
| KR20220079524A (ko) | 2022-06-13 |
| CA3149700A1 (en) | 2021-02-18 |
| AU2020327659A1 (en) | 2022-02-24 |
| EP4010030A1 (en) | 2022-06-15 |
| CN114615998B (zh) | 2025-05-23 |
| GB201911403D0 (en) | 2019-09-25 |
| BR112022002309A2 (pt) | 2022-04-26 |
| CN120837670A (zh) | 2025-10-28 |
| WO2021028666A1 (en) | 2021-02-18 |
| MX2022001712A (es) | 2022-05-13 |
| IL290424A (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522431627B1 (ar) | متقارن واستخداماته | |
| RU2486198C2 (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| PH12022500032A1 (en) | Conjugates of a cell-binding molecule with camptothecin analogs | |
| EA200601168A1 (ru) | КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| WO2019136180A3 (en) | Heteroduplex nucleic acid molecules and uses thereof | |
| MX2026000051A (es) | Peptidos penetrantes celulares | |
| TW200738877A (en) | Immunostimulatory oligoribonucleotides | |
| NZ790263A (en) | Exon skipping compositions for treating muscular dystrophy | |
| CY1111232T1 (el) | Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης | |
| EA201992081A1 (ru) | Конъюгирование цитотоксических лекарственных средств посредством бис-связывания | |
| MY176834A (en) | Conjugate biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same | |
| ATE366294T1 (de) | Klebstoffzusammensetzung auf basis von polychloropren-dispersionen | |
| TW200621801A (en) | Antibody molecules having specificity for human IL-17 | |
| MY146566A (en) | Immunogenic peptide carrier conjugates and methods of producing same | |
| PH12021552944A1 (en) | A formulation of a conjugate of a tubulysin analog to a cell-binding molecule | |
| HRP20050416A2 (en) | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives | |
| CL2024001450A1 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este | |
| WO2014057436A3 (en) | Anticancer conjugate | |
| MX2021001546A (es) | Péptidos penetrantes celulares. | |
| AU2017250507A8 (en) | Methods of treatment using chlorotoxin conjugates | |
| WO2021146320A8 (en) | Antibody molecules to c5ar1 and uses thereof | |
| EA202193040A1 (ru) | Конъюгат анти-всма антитела, композиции, содержащие данный конъюгат, и способы его получения и применения | |
| MX337358B (es) | Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos. | |
| WO2005039589A3 (fr) | Modulateurs des canaux cftr | |
| MX2011007108A (es) | Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos. |